Planegg

Researchers are evaluating the persistence of two treatments, upadacitinib UPA and tumor necrosis factor inhibitors TNFi, in adults with moderate to severe active rheumatoid arthritis RA. This observational study is conducted in Germany with about 678 participants across roughly 80 sites. The purpose is to compare how long participants continue their prescribed treatment under real-world conditions over time. Participants will receive either UPA or TNFi treatment as prescribed by their doctors, following local labels and standard care practices. Treatment decisions were made before joining the study and are independent of recruitment. The study will observe participants for up to 24 months to assess retention rates on these treatments. During the study, participants will be monitored regularly according to local care standards. Researchers will collect data on how long participants stay on their assigned treatment, focusing on retention rates over approximately 24 months. Study participation may last up to two years, with recruitment expected to take about 24 months, resulting in a total study duration of about 48 months.

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Researchers are collecting real-world data on advanced prostate cancer to evaluate the role of next-generation imaging NGI, such as PETCT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. This study focuses on men aged 18 or older with confirmed prostate cancer who need imaging to assess possible metastases either at diagnosis or after relapse. It aims to understand when NGI should be used, how it influences treatment decisions, and its impact on patient outcomes. Participants will receive standard care without experimental treatments. Imaging will be done using either conventional methods, NGI, or both, according to local clinical practice and guidelines. The study includes a cross-sectional observation to evaluate imaging benefits and a longitudinal observation to assess survival outcomes and treatment response based on the imaging approach used. During the study, data will be collected from medical records including patient demographics, medical history, tumor characteristics, and imaging results. Researchers will track the proportion of patients requiring each imaging type and changes in treatment prompted by imaging results within 4 to 6 weeks. The study involves no additional procedures beyond routine care, and participation will continue until the study end in December 2026.

Researchers are evaluating the real-world clinical outcomes and patient-reported experiences of adults with systemic lupus erythematosus SLE who start treatment with subcutaneous anifrolumab. This prospective, single-arm, multicenter, non-interventional study focuses on patients who have not previously used anifrolumab subcutaneously or intravenously. The study aims to describe disease activity, including remission and lupus low disease activity states, quality of life, medication patterns, flares, and organ damage over time. Participants will receive subcutaneous anifrolumab as part of their routine care, with treatment decisions made independently of the study. The study follows patients for 24 months to capture long-term disease control, medication use, and organ damage progression. Data collected include clinical assessments and patient-reported outcomes in a real-life setting without altering usual treatment. During the 24-month observation period, participants will be evaluated at routine visits where disease activity, treatment patterns, quality of life, fatigue, flares, and organ damage are measured. Researchers will review outcomes such as remission rates, time to remission, and sustained disease control. Patient questionnaires and clinical assessments will help track these measures, providing insights into long-term disease management and treatment effects in everyday practice.